1. Introduction {#sec1-pharmaceuticals-13-00056}
===============

According to the World Health Organization, the prevalence of obesity has been increasing globally \[[@B1-pharmaceuticals-13-00056]\]. In 2017, 2 billion and 650 million people were estimated to be overweight or obese, respectively. Thailand is an example of a country with a growing obese population \[[@B2-pharmaceuticals-13-00056]\]. Thailand has the second largest prevalence of obesity among Southeast Asian countries, and approximately 32% of the population is overweight \[[@B3-pharmaceuticals-13-00056]\]. Several drugs have been developed to treat obesity in conjunction with diet control and exercise \[[@B4-pharmaceuticals-13-00056]\]. Drugs exert positive effects on weight by inhibiting the absorption of lipids from the gastrointestinal tract or reducing food intake through suppressing appetite. However, some of the currently available anti-obesogenic drugs have been withdrawn from the market due to their adverse effects \[[@B4-pharmaceuticals-13-00056]\]. Hence, new drugs are continuously being studied.

Anti-obesogenic drugs are mainly prescribed for patients with severe obesity. Thus, alternative methods are needed for people with mild obesity or for those who want to prevent obesity. Traditional remedies that utilize various medicinal plants represent one treatment option for such people. Whereas regular exercise or diet modification to avoid obesity can be difficult for individuals, the consumption of medicinal plants is relatively easy, making them good alternatives. Additionally, various types of plants are used as traditional remedies in Thailand, and because several medicinal plants are available in Thailand, they are inexpensive compared with developed medicines. In addition, medicinal plants are generally used as food ingredients in Thailand, making them familiar and readily available from markets \[[@B5-pharmaceuticals-13-00056]\].

Currently, there is limited knowledge concerning the anti-obesogenic potential of medicinal plants in Thailand. Thus, this study aimed to evaluate the anti-obesogenic potential of Thai medicinal plants which are readily available in the markets in Thailand ([Table 1](#pharmaceuticals-13-00056-t001){ref-type="table"}). Most research for this purpose uses a single bio-assay to evaluate the potential of each plant to select a suitable candidate for further research. However single bio-assays may only reflect a part of the therapeutic potential. In the human body, multiple and complex steps are related to the development of obesity. Thus, by combining multiple bio-assays, the results are more likely to reflect the potential of medicinal plants and they will provide more valid information, which will increase the chance of obtaining successful results in further studies such as in vivo and clinical experiments. Thus, in this study, we used three in vitro assays (pancreatic lipase inhibition assay, lipolysis enhancement activity assay, and lipid accumulation reduction assay) to evaluate the anti-obesogenic potential of Thai medicinal plants and select the best candidates.

2. Results {#sec2-pharmaceuticals-13-00056}
==========

2.1. Screening {#sec2dot1-pharmaceuticals-13-00056}
--------------

Seventy Thai medicinal plant extracts were screened for their ability to inhibit pancreatic lipase activity at a concentration of 0.5 mg/mL, enhance lipolysis, and reduce lipid accumulation at a concentration of 0.05 mg/mL in order to select initial candidates. Each method had a specific criterion for efficacy as written below. Plants exhibiting activity in at least two in vitro assays were considered candidates for further analysis. The detailed results of these assays are summarized in [Table S1](#app1-pharmaceuticals-13-00056){ref-type="app"}.

### 2.1.1. Pancreatic Lipase Inhibition {#sec2dot1dot1-pharmaceuticals-13-00056}

Pancreatic lipase is involved in the digestion of lipids in food, which represent one of the major causes of obesity. Inhibition of this enzyme decreases the absorption of lipids, and this strategy is known to effectively prevent obesity. The inhibitory activities of 70 Thai plant extracts against porcine pancreatic lipase were examined. The criterion for positivity in this assay was an inhibition rate higher than 55%, which is the average inhibition rate of cetilistat, the positive control used in this experiment. Twenty-seven extracts met this criterion: *Tinospora crispa* (L.) Hook. f. and Thomson, *Thunbergia laurifolia* Lindl., *Momordica charantia* L., *Amomum testaceum* Ridl., *Lagerstroemia speciose* (L.) Pers., *Andrographis paniculate* (Burm.f.) Nees, *Pluchea indica* (L.) Less., *Barleria lupulina* Lindl., *Syzygium aromaticum* (L.) Merr. and L.M.Perry, *Piper retrofractum* Vahl, *Curcuma aeruginosa* Roxb., *Morus alba* L., *Cymbopogon nardus* (L.) Rendle, *Ventilago denticulate* Willd., *Zingiber montanum* (J.Koenig) Link ex A. Dietr, *Boesenbergia rotunda* (L.) Mansf., *Erythrina subumbrans* (Hassk.) Merr., *Glycyrrhiza glabra* (L.), *Peltophorum pterocarpum* (DC.) K. Heyne, *Bridelia ovata* Decne., *Cleome viscosa* L., *Cladogynos orientalis* Zipp. Ex Span., *Dracaena cochinchinensis* (Lour.) S.C.Chen, *Wrightia arborea* (Dennst.) Mabb., *Cyperus rotundus* L., *Acacia concinna* (Willd.) DC., and *Caesalpinia sappan* L.

### 2.1.2. Lipolysis Enhancement {#sec2dot1dot2-pharmaceuticals-13-00056}

Lipids are stored in adipocytes, and their levels in adipocytes are directly correlated with the obesity status of a person. The amount of lipids stored in adipocytes is controlled by the balance between lipogenesis and lipolysis. Thus, inhibiting lipogenesis or enhancing lipolysis will decrease the amount of lipids in adipocytes and exert favorable effects for treating or preventing obesity. 3T3-L1 adipocytes were used to evaluate the lipolysis-enhancing activities of Thai medicinal plant extracts, and the criterion for positivity was a greater than 30% increase in lipolysis compared with the effects of the control. Nine extracts satisfied this criterion: *Terminalia chebula* Retz., *Rauvolfia serpentine* (L.) Benth. Ex Kurz, *Cissus quadrangularis* L., *Chromolaena odorata* (L.) R.M.King and H.Rob., *Tiliacora triandra* Diels, *C. nardus*, *Eurycoma longifolia* Jack, *C. rotundus*, and *A. concinna*.

### 2.1.3. Lipid Accumulation Suppression {#sec2dot1dot3-pharmaceuticals-13-00056}

The accumulation of lipids in 3T3-L1 adipocytes was measured to evaluate the effect of Thai medicinal plant extracts on lipogenesis. Although lipolysis enhancement also reduces lipid levels in adipocytes, assessment of both lipolysis enhancement and lipid accumulation suppression will clarify whether inhibition of lipogenesis or enhancement of lipolysis is the cause of reduced lipid accumulation in 3T3-L1 adipocytes. The criterion for positivity was a greater than 10% decrease in lipid accumulation compared with the control findings, and seven extracts satisfied this criterion: *M. alba*, *Ocimum tenuiflorum* L., *T. triandra*, *E. longifolia*, *C. rotundus*, *Jasminum sambac* (L.) Aiton, and *C. sappan*.

2.2. Anti-Obesogenic Potential of Identified Candidate Plants {#sec2dot2-pharmaceuticals-13-00056}
-------------------------------------------------------------

The results identified seven medicinal plants with satisfactory effects in at least two of the three assays. The selected medicinal plants were *M. alba*, *T. triandra*, *C. nardus*, *E. longifolia*, *C. rotundus*, *A. concinna*, and *C. sappan*. These plants were subjected to further analyses using the same methods with different concentrations to more precisely reveal their potential. A cell viability assay was also performed to detect the cytotoxic effects of the extracts.

### 2.2.1. Pancreatic Lipase Inhibition by the Candidate Extracts {#sec2dot2dot1-pharmaceuticals-13-00056}

The inhibitory effects of the candidate plant extracts on pancreatic lipase activity were evaluated at concentrations of 0.25, 0.5, and 1.0 mg/mL ([Figure 1](#pharmaceuticals-13-00056-f001){ref-type="fig"}). Based on the results, the candidate plants were divided into three groups according to their pancreatic lipase-inhibitory activity (low, moderate, and high). The group with low inhibitory activity, consisting of plants that inhibited lipase activity by no more than 70% at the highest tested concentration, consisted of *E. longifolia* (31% ± 7.4%), *C. rotundus* (61% ± 2.3%), and *T. triandra* (70% ± 2.7%). The plants with moderate inhibitory activity, which inhibited lipase activity by more than 70% at the highest concentration but not at lower concentration, included *M. alba* (90% ± 20.6% at 1.0 mg/mL) and *C. nardus* (91% ± 1.5% at 1.0 mg/mL). The group with high inhibitory activity, which inhibited lipase activity by more than 70% at all concentrations, consisted of *A. concinna* and *C. sappan*.

### 2.2.2. Lipolysis Enhancement by the Candidate Extracts {#sec2dot2dot2-pharmaceuticals-13-00056}

The abilities of the candidate plant extracts to enhance lipolysis were analyzed at concentrations of 0.05, 0.1, and 0.2 mg/mL ([Figure 2](#pharmaceuticals-13-00056-f002){ref-type="fig"}). Based on the results, the extracts were categorized into three groups (no, relatively weak, and relatively strong activity). Two extracts, namely *M. alba* and *C. sappan* exhibited no ability to enhance lipolysis, whereas *T. triandra* and *A. concinna* exhibited relatively weak activity. Of these plants, a negative correlation was observed between the concentration of *A. concinna* and its lipolysis-enhancing effects. Cell viability testing (Figure 5) suggested that cytotoxicity was the cause of this negative correlation. Thus, lower concentrations (0.00625, 0.0125, and 0.025 mg/mL) were used for *A. concinna*, and the results revealed a positive correlation at these concentrations, confirming the interference of cytotoxicity at high concentrations ([Figure 3](#pharmaceuticals-13-00056-f003){ref-type="fig"}). Three plants namely, *C. nardus*, *C. rotundus*, and *E. longifolia*, increased lipolysis by more than 50% relative to the control. We would like to note that *E. longifolia* displayed the highest activity among the seven candidate plants.

### 2.2.3. Lipid Accumulation Suppression by the Candidate Extracts {#sec2dot2dot3-pharmaceuticals-13-00056}

The abilities of the candidate plant extracts to reduce lipid accumulation were evaluated at concentrations of 0.05, 0.1, and 0.2 mg/mL ([Figure 4](#pharmaceuticals-13-00056-f004){ref-type="fig"}). The candidate plants were divided into two groups based on their potential to reduce lipid accumulation in adipocytes (yes or no). *M. alba*, *C. nardus*, and *C. rotundus* exhibited no ability to reduce lipid accumulation, whereas the remaining plants displayed the potential to reduce lipid accumulation. Among them, *C. sappan* exhibited constant activity at all tested concentrations, whereas the effects of *A. concinna*, *E. longifolia*, and *T. triandra* increased with the increasing concentration.

### 2.2.4. Cell Viability {#sec2dot2dot4-pharmaceuticals-13-00056}

To observe the toxicity of medicinal plant extracts in adipocytes, cell viability after treatment with the plant extracts was examined ([Figure 5](#pharmaceuticals-13-00056-f005){ref-type="fig"}). Excluding weak toxicity for *A. concinna*, none of the extracts were toxic at the tested concentrations.

3. Discussion {#sec3-pharmaceuticals-13-00056}
=============

Numerous studies have focused on screening medicinal plants for effects against various diseases. In general, a single bio-assay is employed for this screening. The present study employed multiple assays to investigate both the digestion of lipids in the gastrointestinal tract and lipid synthesis/metabolism in adipocytes, both of which are important processes in the development of obesity ([Table 2](#pharmaceuticals-13-00056-t002){ref-type="table"}).

Among 70 Thai medicinal plants, seven medicinal plants namely, *M. alba*, *C. nardus*, *C. rotundus*, *C. sappan*, *E. longifolia*, *T. triandra*, and *A. concinna* were selected as candidates after the first round of screening. These medicinal plants were then subjected to a second round of screening using the same assays but at different concentrations, in addition to a cell viability assay, to select promising candidates.

Despite being selected as a candidate in the first round of screening, *M. alba* leaf extract displayed only moderate inhibitory effects on pancreatic lipase during the second round of screening, and the plant was not considered a preferred candidate in this study. However, this plant has been studied for its beneficial effects on obesity-related fatty liver disease \[[@B7-pharmaceuticals-13-00056]\]. In this prior study, *M. alba* extract was administered to high-fat diet (HFD)-fed mice for 12 weeks. Although there was no effect on body weight, the extract regulated hepatic lipid metabolism by attenuating liver X receptor α-mediated lipogenesis and upregulating lipolysis-associated markers such as lipoprotein lipase.

We found that *C. nardus* leaves exhibited moderate inhibitory effects on pancreatic lipase and strong lipolysis-enhancing effects. *C. nardus* leaves have been traditionally used in health products including soaps, anti-mosquito oils, candles, and pain-relieving oils \[[@B8-pharmaceuticals-13-00056]\]. Interestingly, a study by Batubara et al. reported the weight-reducing effects of citronella oil an essential oil extracted from *C. nardus* which contains *R*-citronellal, neryl acetate, citronellyl acetate, geraniol, and β-citronellol, in obese rats \[[@B8-pharmaceuticals-13-00056]\]. Inhalation of this essential oil led to increased sympathetic nerve activity and decreased appetite, weight gain, and cholesterol levels. The anti-obesogenic effects of consumption of this leaf have not yet been studied.

Next, *C. rotundus* rhizomes have been traditionally used to treat diabetes, pyrosis, inflammation, malaria, and stomach/gastrointestinal disorders \[[@B9-pharmaceuticals-13-00056]\]. The plant has not been used to treat obesity, but previous studies have investigated the effects of *C. rotundus* tubers on obesity using in vitro and in vivo methods \[[@B10-pharmaceuticals-13-00056],[@B11-pharmaceuticals-13-00056]\]. Lamaure et al. administrated 45 or 220 mg/kg/day *C. rotundus* tuber hexane extract to Zucker rats for 60 days and observed a reduction in weight gain without an effect on food consumption \[[@B10-pharmaceuticals-13-00056]\]. In the same study, they described the ability of the extract to enhance lipolysis by 3T3-F442 adipocytes. In accordance with their result, *C. rotundus* rhizomes strongly enhanced lipolysis and weakly inhibited pancreatic lipase in the present study. Although reduced lipid accumulation was not observed in 3T3-L1 adipocytes in our experiment, the combination of lipase inhibition and lipolysis enhancement might be important for the reduction of weight gain observed in the study by Lamaure et al.

Furthermore, *C. sappan* heartwood strongly inhibited pancreatic lipase activity and reduced lipid accumulation reduction at all tested concentrations in the present study. Due to the lack of effects on lipolysis, the inhibitory effects of the extract on lipid accumulation are assumed to arise from the reduction of lipid synthesis in 3T3-L1 cells. The constituents in this plant have been previously studied. The heartwood of *C. sappan* contains flavonoids such as protosappanin and hematoxylin, and the main constituent among them is brazilin \[[@B12-pharmaceuticals-13-00056]\]. Brazilein, the dehydrogenated form of brazilin, was also isolated from the heartwood of *C. sappan* and was demonstrated to have anti-obesogenic activity. In particular, the compound inhibited the differentiation of 3T3-L1 preadipocytes through suppressing the induction of peroxisome proliferator-activated receptor γ, the master regulator of adipogenesis \[[@B13-pharmaceuticals-13-00056]\]. Together with our current result illustrating its potential to regulate lipid digestion and synthesis, *C. sappan* is considered a promising candidate for the treatment of obesity.

Moreover, *E. longifolia* roots displayed low pancreatic lipase-inhibitory activity but strong potential to enhance lipolysis and reduce lipid accumulation in 3T3-L1 adipocytes. *E. longifolia* is a well-known medicinal plant in the Asian region, and several studies have described the potential of its roots to treat obesity \[[@B14-pharmaceuticals-13-00056],[@B15-pharmaceuticals-13-00056],[@B16-pharmaceuticals-13-00056]\]. For instance, our research group previously explored the bioactive compounds of *E. longifolia* roots and their lipolysis-enhancing activities in a cell-based assay \[[@B15-pharmaceuticals-13-00056]\]. In the report, we identified eurycomanone and 13β,21-epoxyeurycomanone as the bioactive compounds in the roots of *E. longifolia*. The two quassinoids enhanced lipolysis with EC~50~s of 14.6 and 8.6 μM, respectively. An in vivo study also demonstrated the efficacy of this plant. The study found that a standardized quassinoid-enriched fraction of *E. longifolia* reduced body weight gain, adipose tissue hypertrophy, and serum glycerol levels in mice with HFD induced obesity \[[@B16-pharmaceuticals-13-00056]\]. Furthermore, clinical testing illustrated that consumption of the *E. longifolia* extract together with exercise enhanced lipolysis \[[@B14-pharmaceuticals-13-00056]\]. Thus, in addition to being identified as a promising candidate in this study, *E. longifolia* has been proven effective for the treatment of obesity by several researchers.

The last two candidates, *T. triandra* roots and *A. concinna* pods, are interesting candidates for anti-obesity purposes given that they have not been studied for this indication previously. The roots of *T. triandra* are traditionally employed for the treatment of cancer, fever, and malaria, but not obesity \[[@B17-pharmaceuticals-13-00056]\]. Conversely, the leaf extract of *T. triandra* has anti-obesogenic potential based on its ability to inhibit pancreatic lipase activity with an IC~50~ of 273.5 µg/mL \[[@B18-pharmaceuticals-13-00056]\]. Thus, our findings regarding the potential of the roots of the plant to inhibit pancreatic lipase, stimulate lipolysis, and reduce lipid accumulation in adipocytes should increase its potential utility for the treatment and prevention of obesity. There has been no report on the anti-obesogenic effects of *A. concinna*. Our result that *A. concinna* pods strongly inhibit pancreatic lipase, weakly stimulate lipolysis, and reduce lipid accumulation in adipocytes is a novel finding for this plant. Although *A. concinna* was found to be cytotoxic at high concentrations, it can be a good candidate for treating obesity at limited doses.

In conclusion, we screened 70 Thai medicinal plants using three in vitro methods for their anti-obesogenic potential, and seven plants were selected as candidates. Each candidate is expected to emerge as a potential candidate for obesity treatment. In particular, *T. triandra*, *E. longifolia*, and *A. concinna* exhibited activity in all three assays, suggesting their greater potential. In fact, the potential of *E. longifolia* has been demonstrated in in vivo experiments. Through further study of the other two plants, we hope to reveal that the combined in vitro assay is effective for screening potential medicinal plants and clarify the potential of *T. triandra* and *A. concinna* for treating obesity.

4. Materials and Methods {#sec4-pharmaceuticals-13-00056}
========================

4.1. Preparation of Medicinal Plant Extracts {#sec4dot1-pharmaceuticals-13-00056}
--------------------------------------------

Seventy dried Thai medicinal plants were purchased from a local store in Samut Prakan, Thailand. The plant samples were stored at the Ministry of Public Health, Department of Thai Traditional and Alternative Medicine (Thailand), and voucher specimens (authentic crude drug) were issued for use as the medicinal plants' species references. The plants were ground into fine small particles, and 5 g of each sample were soaked in 50% (*v*/*v*) aqueous methanol for 3 days. The supernatant of each suspension was filtered through filter paper, and the filtrates were evaporated to obtain the extracts used in the assays.

4.2. Pancreatic Lipase Inhibition Assay {#sec4dot2-pharmaceuticals-13-00056}
---------------------------------------

Lipase inhibition was examined using Han's method with modifications \[[@B19-pharmaceuticals-13-00056]\]. An emulsified solution of l-α-lecithin (Sigma-Aldrich, St. Louis, MO, USA; P4279, 10 mg), triolein (16 mg), and sodium taurocholate (5 mg) in Tris buffer (13 mM Tris, 150 mM NaCl, 1.3 mM CaCl~2~, pH 8.0, 9.0 mL) was used as a substrate. Porcine pancreatic lipase (Sigma, L3126, 4.5 mg) was dissolved in Tris buffer (30 mL) and used as an enzyme solution. The substrate (200 μL) and sample (100 μL, dissolved in 50% (*v*/*v*) aqueous dimethyl sulfoxide (DMSO)) were preincubated at 37 °C for 5 min. The reaction was started by adding the enzyme solution (100 μL) and allowed to continue for 30 min at 37 °C. The reaction was then stopped by adding 1 M hydrochloric acid (20 μL), and the liberated oleic acids were extracted using by hexane (600 μL). The hexane layer (300 μL) was dried and dissolved in DMSO (100 μL), and the oleic acid content was quantitated using a NEFA C-test Wako kit (Fujifilm Wako Pure Chem. Ind. Ltd., Osaka, Japan). Cetilistat (8 μM) was used as a positive control. The experiments were conducted in duplicate and repeated at least twice, and the representative values (mean ± standard deviation (SD)) are presented in the figures and tables.

4.3. Culture and Differentiation of 3T3-L1 Cells {#sec4dot3-pharmaceuticals-13-00056}
------------------------------------------------

Murine 3T3-L1 cells (JCRB9014) were obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). 3T3-L1 cells were cultured in 96-well plates to confluence using basic medium (Dulbecco's modified Eagle's medium (DMEM) containing 10% (*v*/*v*) fetal bovine serum, 100 U/mL penicillin G potassium salt, 100 μg/mL streptomycin sulfate, and 50 μg/mL gentamicin sulfate). The cells were grown at 37 °C in a 10% carbon dioxide atmosphere. One day after reaching confluence, which was designated Day 0, cells were induced to undergo differentiation by changing the medium to differentiation medium, which was the basic medium containing 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.25 µM dexamethasone, and 10 µg/mL insulin. The medium was changed to insulin medium (the basic medium supplemented with 0.5 μg/mL insulin) on Days 2--4. From Day 4, the cell treatment differed between the lipolysis enhancement and lipid accumulation reduction assays.

4.4. Lipolysis Enhancement Assay {#sec4dot4-pharmaceuticals-13-00056}
--------------------------------

Cells were maintained in basic medium from Day 6 until Day 8. The plant extracts (dissolved in 10% (*v*/*v*) DMSO) were diluted with DMEM without phenol red and added to the cells. After 24 h of incubation, the lipolysis-enhancing activity of each extract was measured by quantitating the content of glycerol released from adipocytes into the medium. The supernatants were taken, mixed with free glycerol reagent (Sigma-Aldrich), and subjected to measurement according to the manufacturer's instructions. The absorbance was measured at 540 nm using a Synergy™ MX microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). Isoproterenol hydrochloride and 0.1% DMSO were used as the positive and negative controls, respectively. The experiments were repeated at least twice (*n* = 8 each), and the representative values (mean ± SD) are presented in the figures and tables. Lipolysis enhancement activity (% increase relative to control) was calculated according to the following formula:$$\%~\mathbf{increase}~\mathbf{to}~\mathbf{control} = \left\{ {\left( \frac{\mathbf{A}_{540}\mathbf{Sample} - \mathbf{A}_{540}\mathbf{Blank}}{\mathbf{A}_{540}\mathbf{Control} - \mathbf{A}_{540}\mathbf{Blank}} \right) - 1} \right\} \times 100.$$

4.5. Lipid Accumulation Suppression Assay {#sec4dot5-pharmaceuticals-13-00056}
-----------------------------------------

The plant extracts (dissolved in 10% (*v*/*v*) DMSO) were diluted in insulin-containing medium and added to the cells on Day 4. Then, the plant extracts were diluted in basic medium and added to the cells again on Day 6, followed by 3 days of incubation. The lipid content of the adipocytes was measured using AdipoRed™ reagent (LONZA, Tokyo, Japan). *Brucea javanica* extract (0.05 mg/mL), which is known to reduce lipid accumulation, was used as the positive control \[[@B20-pharmaceuticals-13-00056]\], and 0.1% DMSO was used as the negative control. The experiments were repeated at least twice (*n* = 8 each), and representative values (mean ± SD) are presented in the figures and tables. Lipid accumulation reduction activity (% decrease relative to control) was calculated as follows:$$\%~\mathbf{decrease}~\mathbf{of}~\mathbf{control} = \left\{ {1 - \left( \frac{\mathbf{A}_{540}\mathbf{Sample}}{\mathbf{A}_{540}\mathbf{Control}} \right)} \right\} \times 100.$$

4.6. Cell Viability Assay {#sec4dot6-pharmaceuticals-13-00056}
-------------------------

Cell viability was measured using Cell Counting Kit-8 (CCK-8; Dojindo Lab., Kumamoto, Japan) in accordance with the manufacturer's instructions. In brief, following 24 h of treatment with each extract, cells were incubated with CCK-8 reagent for 3 h. The absorbance of the supernatant was measured at 540 nm. Triton X-100 was used as the positive control for reference for cytotoxicity measurements. The experiments were repeated at least twice (*n* = 8 each), and representative values are presented in the figures or tables.

4.7. Statistics {#sec4dot7-pharmaceuticals-13-00056}
---------------

The obtained data were statistically analyzed by one-way analysis of variance coupled with Tukey's test. Differences were considered statistically significant at *p* \< 0.05.
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![Pancreatic lipase-inhibitory activities of the candidate plant extracts. Cetilistat (positive control) concentration was 8 µM. Data are expressed as means ± standard deviation. Means with different letters are significantly different (Tukey's test, *p* \< 0.05).](pharmaceuticals-13-00056-g001){#pharmaceuticals-13-00056-f001}

![Lipolysis enhancement activity of the candidate plant extracts. Isoproterenol (ISP, positive control) was used at 2.5 µM. Data are expressed as means ± standard deviation. Means with different letters are significantly different (Tukey's test, *p* \< 0.05).](pharmaceuticals-13-00056-g002){#pharmaceuticals-13-00056-f002}

![Lipolysis enhancement activity of the *Acacia concinna* extract. Data are expressed as means ± standard deviation. Means with different letters are significantly different (Tukey's test, *p* \< 0.05).](pharmaceuticals-13-00056-g003){#pharmaceuticals-13-00056-f003}

![Lipid accumulation reduction activities of the candidate plant extracts. *Brucea javanica* (positive control) was used at 0.05 mg/mL. Data are expressed as means ± standard deviation. Means with different letters are significantly different (Tukey's test, *p* \< 0.05).](pharmaceuticals-13-00056-g004){#pharmaceuticals-13-00056-f004}

![Cell viability after treatment with the candidate plant extracts. Triton X-100 (positive control) was used at 0.1% *v*/*v*. Data are expressed as means ± standard deviation. Means with different letters are significantly different (Tukey's test, *p* \< 0.05).](pharmaceuticals-13-00056-g005){#pharmaceuticals-13-00056-f005}

pharmaceuticals-13-00056-t001_Table 1

###### 

List of the selected Thai medicinal plants.

  Scientific Name \[[@B6-pharmaceuticals-13-00056]\]                      Voucher Specimens (Authentic Crude Drug)   Local Name   Family             Part Used        
  ----------------------------------------------------------------------- ------------------------------------------ ------------ ------------------ ---------------- ---------------------
  *Acacia concinna* (Willd.) DC.                                          WR063                                      10000621     Som poi            Fabaceae         Pods
  *Allium sativum* L.                                                     WR001                                      10000559     Kra thiam          Amaryllidaceae   Clove
  *Amomum testaceum* Ridl.                                                WR014                                      10000572     Krawan             Zingiberaceae    Seeds
  *Andrographis paniculata* (Burm.f.) Nees                                WR025                                      10000583     A thalai chon      Acanthaceae      Branches and leaves
  *Angelica sinensis* (Oliv.) Diels                                       WR049                                      10000607     Kot chiang         Apiaceae         Roots
  *Averrhoa carambola* L.                                                 WR070                                      10000628     Ma fueang          Oxalidaceae      Branches and bark
  *Azadirachta indica* A.Juss.                                            WR062                                      10000620     Sadao              Meliaceae        Branches
  *Baliospermum solanifolium* (Burm.) Suresh                              WR066                                      10000624     Tong tag           Euphorbiaceae    Roots
  *Barleria lupulina* Lindl.                                              WR027                                      10000585     Salet phang phon   Acanthaceae      Branches and leaves
  *Boesenbergia rotunda* (L.) Mansf.                                      WR043                                      10000601     Krachai            Zingiberaceae    Roots
  *Bridelia ovata* Decne.                                                 WR048                                      10000606     Ma ka              Phyllanthaceae   Branches and leaves
  *Butea superba* Roxb.                                                   WR040                                      10000598     Kwao khruea        Fabaceae         Bark
  *Caesalpinia sappan* L.                                                 WR067                                      10000625     Fang               Fabaceae         Heartwood
  *Carthamus tinctorius* L.                                               WR004                                      10000562     Kham foi           Asteraceae       Flower
  *Centella asiatica* (L.) Urb.                                           WR022                                      10000580     Bua bok            Apiaceae         Stems
  *Chromolaena odorata* (L.) R.M.King and H.Rob.                          WR023                                      10000581     Sap suea           Asteraceae       Branches
  *Cinnamomum iners* Reinw. ex Blume                                      WR053                                      10000611     Op choei thai      Lauraceae        Branches
  *Cissus quadrangularis* L.                                              WR020                                      10000578     Phet sang khat     Vitaceae         Bark
  *Citrus aurantiifolia* (Christm.) Swingle                               WR058                                      10000616     Ma nao             Rutaceae         Leaves
  *Citrus hystrix* DC.                                                    WR052                                      10000610     Ma krut            Rutaceae         Skin
  *Cladogynos orientalis* Zipp. ex Span.                                  WR051                                      10000609     Chetta phang khi   Euphorbiaceae    Roots
  *Cleome viscosa* L.                                                     WR050                                      10000608     Phak sian phi      Cleomaceae       Branches and leaves
  *Clitoria ternatea* L.                                                  WR009                                      10000567     Anchan             Fabaceae         Flowers
  *Croton fluviatilis* Esser                                              WR068                                      10000626     Plao noi           Euphorbiaceae    Trunk and bark
  *Croton persimilis* Müll.Arg.                                           WR069                                      10000627     Plao yai           Euphorbiaceae    Trunk and bark
  *Curcuma aeruginosa* Roxb.                                              WR033                                      10000591     Wan maha mek       Zingiberaceae    Rhizomes
  *Cymbopogon citratus* (DC.) Stapf                                       WR061                                      10000619     Ta khrai           Poaceae          Stems
  *Cymbopogon nardus* (L.) Rendle                                         WR037                                      10000595     Ta khrai hom       Poaceae          Leaves
  *Cyperus rotundus* L.                                                   WR056                                      10000614     Haeo mu            Cyperaceae       Rhizomes
  *Derris elliptica* (Wall.) Benth.                                       WR065                                      10000623     Hang lai daeng     Fabaceae         Bark
  *Dracaena cochinchinensis* (Lour.) S.C.Chen                             WR054                                      10000612     Chan daeng         Asparagaceae     Bark
  *Erythrina subumbrans* (Hassk.) Merr.                                   WR044                                      10000602     Thong lang         Fabaceae         Bark
  *Eurycoma longifolia* Jack                                              WR041                                      10000599     Pla lai phueak     Simaroubaceae    Roots
  *Glycyrrhiza glabra* L.                                                 WR046                                      10000604     Cha em             Fabaceae         Branches
  *Helicteres isora* L.                                                   WR003                                      10000561     Po bit             Malvaceae        Pods
  *Hibiscus sabdariffa* L.                                                WR002                                      10000560     Krachiap daeng     Malvaceae        Flower
  *Hydnophytum formicarum* Jack                                           WR059                                      10000617     Hua roi ru         Rubiaceae        Trunk
  *Jasminum sambac* (L.) Aiton                                            WR057                                      10000615     Mali               Oleaceae         Flowers
  *Lagerstroemia speciosa* (L.) Pers.                                     WR021                                      10000579     Inthanin           Lythraceae       Leaves
  *Mimosa pudica* L.                                                      WR007                                      10000565     Maiyarap           Fabaceae         Branches and leaves
  *Momordica charantia* L.                                                WR012                                      10000570     Ma ra khi nok      Cucurbitaceae    Branches and leaves
  *Morinda citrifolia* L.                                                 WR060                                      10000618     Yo                 Rubiaceae        Fruit
  *Moringa oleifera* Lam.                                                 WR013                                      10000571     Marum              Moringaceae      Seeds
  *Morus alba* L.                                                         WR034                                      10000592     Mon                Moraceae         Leaves
  *Nelumbo nucifera* Gaertn.                                              WR045                                      10000603     Bua luang          Nelumbonaceae    Stamens
  *Ocimum tenuiflorum* L.                                                 WR035                                      10000593     Ka phrao           Lamiaceae        Branches
  *Orthosiphon aristatus* (Blume) Miq.                                    WR006                                      10000564     Ya nuat maeo       Lamiaceae        Branches and leaves
  *Oxyceros horridus* Lour.                                               WR029                                      10000587     Khat khao          Rubiaceae        Fruits
  *Paederia linearis* Hook.f.                                             WR032                                      10000590     Tot mu tot ma      Rubiaceae        Branches
  *Peltophorum pterocarpum* (DC.) K.Heyne                                 WR047                                      10000605     Khi lek            Fabaceae         Core
  *Phyllanthus emblica* L.                                                WR016                                      10000574     Ma kham pom        Phyllanthaceae   Seeds
  *Physalis angulata* L.                                                  WR024                                      10000582     Thong theng        Solanaceae       Barks
  *Piper nigrum* L.                                                       WR030                                      10000588     Phrik thai         Piperaceae       Seeds
  *Piper retrofractum* Vahl                                               WR031                                      10000589     Di pli             Piperaceae       Fruits
  *Piper sarmentosum* Roxb.                                               WR010                                      10000568     Cha phlu           Piperaceae       Branches and leaves
  *Pluchea indica* (L.) Less.                                             WR026                                      10000584     Khlu               Asteraceae       Branches and leaves
  *Pueraria candollei* var. *mirifica* (Airy Shaw and Suvat.) Niyomdham   WR039                                      10000597     Kwao khruea khao   Fabaceae         Bark
  *Rauvolfia serpentina* (L.) Benth. ex Kurz                              WR019                                      10000577     Rayom              Apocynaceae      Roots
  *Rhinacanthus nasutus* (L.) Kurz                                        WR008                                      10000566     Thong pharchang    Acanthaceae      Branches and leaves
  *Solanum sanitwongsei* W. G. Craib                                      WR015                                      10000573     Ma waeng           Solanaceae       Branches and leaves
  *Syzygium aromaticum* (L.) Merr. and L.M.Perry                          WR028                                      10000586     Kan phlu           Myrtaceae        Buds
  *Tectona grandis* L.f.                                                  WR018                                      10000576     Sak                Lamiaceae        Bark
  *Terminalia chebula* Retz.                                              WR017                                      10000575     Samo thai          Combretaceae     Seeds
  *Thunbergia laurifolia* Lindl.                                          WR011                                      10000569     Rang chuet         Acanthaceae      Bark
  *Tiliacora triandra* Diels                                              WR036                                      10000594     Ya nang            Menispermaceae   Roots
  *Tinospora crispa* (L.) Hook. f. and Thomson                            WR005                                      10000563     Bora phet          Menispermaceae   Branches and leaves
  *Ventilago denticulata* Willd.                                          WR038                                      10000596     Rang daeng         Rhamnaceae       Bark
  *Ventilago denticulata* Willd.                                          WR064                                      10000622     Rang daeng         Rhamnaceae       Core
  *Wrightia arborea* (Dennst.) Mabb.                                      WR055                                      10000613     Mok man            Apocynaceae      Bark
  *Zingiber montanum* (J.Koenig) Link ex A.Dietr.                         WR042                                      10000600     Phlai              Zingiberaceae    Rhizomes

^1^ Thai traditional medicine crude drug.

pharmaceuticals-13-00056-t002_Table 2

###### 

Summary of the anti-obesogenic potential of the candidate plants.

  Medicinal Plants   Pancreatic Lipase Inhibition   Lipolysis Enhancement   Lipid Accumulation Reduction   Toxicity
  ------------------ ------------------------------ ----------------------- ------------------------------ ----------
  *M. alba*          Medium                         NA \*                   NA                             Negative
  *T. triandra*      Low                            Weak                    Active (CD \*)                 Negative
  *C. nardus*        Medium                         Strong                  NA                             Negative
  *E. longifolia*    Low                            Strong                  Active (CD)                    Negative
  *C. rotundus*      Low                            Strong                  NA                             Negative
  *A. concinna*      High                           Weak                    Active (CD)                    Positive
  *C. sappan*        High                           NA                      Active (constant)              Negative

\* NA: no activity, CD: concentration dependent.
